Muzaffer Uğraklı

7PUBLICATIONS
72CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Aug 27, 2026
Integrated Inflammatory and Nutritional Biomarkers in Metastatic Renal Cell Carcinoma Treated with Second- or Later-Line Nivolumab: A Retrospective Cohort Study.

|Feb 11, 2026
Real-world effectiveness and safety of brigatinib in advanced ALK-positive NSCLC: a nationwide multicenter study by the Turkish Oncology Group.

Salih Tunbekici, Hamit Bal, Oguzcan Kınıkoglu

|Jan 28, 2026
The Impact of Concurrent Proton Pump Inhibitors on Nivolumab Response in Metastatic Non-Small Cell Lung Cancer: A Multicenter Real-Life Study.

Engin Hendem, Mehmet Zahid Koçak, Ayşegül Merç Çetinkaya

|Jun 10, 2024
Comparison of the second-line treatment efficacy in advanced gastric cancer patients previously treated with taxane-based triplet chemotherapy: a Turkish Oncology Group Study.

Kadriye Bir Yücel, Muzaffer Uğraklı, Serhat Sekmek

|Jan 19, 2022
A case of severe vasculitis after FLOT chemotherapy in a patient with metastatic gastric cancer who received multiple line chemotherapy.

Engin Hendem, Mustafa Korkmaz, Muzaffer Uğraklı

|Dec 22, 2021
Pneumonitis associated with Trastuzumab emtansine in a patient with metastatic breast cancer.

Muzaffer Uğraklı, Murat Araz, Aykut Demirkıran

Pageof 2

Frequent Collaborators

6 joint publications

Mehmet Artaç

5 joint publications

Melek Karakurt Eryılmaz

4 joint publications

Murat Araz

3 joint publications

Mustafa Karaağaç